JW (Cayman) Therapeutics Co. Ltd (2126.HK)
HKD 1.58
(3.27%)
HKD 1.58
(3.27%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 877.82 Million CNY | -27.99% |
| 2022 | 914.63 Million CNY | 27.57% |
| 2021 | 716.97 Million CNY | -56.98% |
| 2020 | 1.66 Billion CNY | 160.71% |
| 2019 | 639.2 Million CNY | 446.18% |
| 2018 | 117.03 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 291.25 Million CNY | 0.0% |
| 2023 Q2 | 434.73 Million CNY | 0.0% |
| 2023 FY | 658.61 Million CNY | -27.99% |
| 2023 Q4 | 443.09 Million CNY | 0.0% |
| 2022 Q4 | 459.55 Million CNY | 0.0% |
| 2022 FY | 914.63 Million CNY | 27.57% |
| 2022 Q2 | 455.08 Million CNY | 0.0% |
| 2021 FY | 716.97 Million CNY | -56.98% |
| 2021 Q4 | 434.88 Million CNY | 0.0% |
| 2021 Q2 | 282.09 Million CNY | 0.0% |
| 2020 Q2 | 650.71 Million CNY | 0.0% |
| 2020 FY | 1.66 Billion CNY | 160.71% |
| 2020 Q4 | 1.01 Billion CNY | 0.0% |
| 2019 Q4 | 281.66 Million CNY | 0.0% |
| 2019 Q2 | 357.54 Million CNY | 0.0% |
| 2019 FY | 639.2 Million CNY | 446.18% |
| 2018 Q2 | -67.42 Million CNY | 0.0% |
| 2018 Q1 | -67.42 Million CNY | 0.0% |
| 2018 FY | 117.03 Million CNY | 0.0% |
| 2018 Q4 | -157.97 Million CNY | 0.0% |
| 2017 Q4 | -67.42 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 325.05 Million HKD | -170.059% |
| CK Life Sciences Int'l., (Holdings) Inc. | 739.25 Million HKD | -18.745% |